Hypertension
Conditions
Keywords
Cough, Telmisartan, Bradykinin, Tolerability
Brief summary
In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.
Interventions
Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hypertension * Age \> 18 * ACE-I related cough
Exclusion criteria
* Current treatment with telmisartan * Cholestatic disorders and severe hepatic failure * Allergy to telmisartan * Pregnancy and lactation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough | 4 months after initiation |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events among patients, who had to stop their previous ACE-I treatment due to cough | 4 months after initiation |
Countries
Slovakia
Outcome results
None listed